TY  - GEN
AU  - Denora,Nunzio
AU  - Lopalco,Antonio
AU  - Denora,Nunzio
AU  - Lopalco,Antonio
TI  - Paediatric Formulation: Design and Development
SN  - books978-3-0365-0741-5
PY  - 2021///
CY  - Basel, Switzerland
PB  - MDPI - Multidisciplinary Digital Publishing Institute
KW  - Medicine
KW  - bicssc
KW  - dasatinib
KW  - Duchenne muscular dystrophy
KW  - cyclodextrin inclusion complex
KW  - phase solubility studies
KW  - paediatric age
KW  - liquid formulation
KW  - tumorspheres
KW  - retinoblastoma
KW  - topotecan
KW  - penetration
KW  - confocal microscopy
KW  - poorly water soluble drug
KW  - solubility enhancement
KW  - grinding
KW  - spray congealing
KW  - neglected tropical diseases
KW  - polymorph
KW  - Norvir®
KW  - ritonavir
KW  - poorly soluble compound
KW  - pediatric
KW  - palatability assessment
KW  - bioavailability
KW  - flavor profile
KW  - Interleukin-1
KW  - anakinra
KW  - canakinumab
KW  - innovative biotechnologies
KW  - autoinflammatory disease
KW  - Kawasaki disease
KW  - systemic juvenile idiopathic arthritis
KW  - personalized medicine
KW  - child
KW  - pediatrics
KW  - neonates
KW  - formulation
KW  - product development
KW  - formulation development
KW  - oral
KW  - parenteral
KW  - topical
KW  - inhaled
KW  - intra nasal
KW  - biopharmaceutics
KW  - administration
KW  - excipient
KW  - NICU
KW  - device
KW  - medication error
KW  - dosage form
KW  - modified release
KW  - drug delivery
KW  - paediatric formulation development
KW  - paediatric dosage forms
KW  - chronic myeloid leukemia
KW  - tyrosine kinase inhibitors
KW  - pediatric age
KW  - imatinib
KW  - nilotinb
KW  - ponatinib
KW  - Orodispersible formulation
KW  - pyrazinamide
KW  - pediatric drug delivery
KW  - tuberculosis
KW  - design of experiments
KW  - children
KW  - edible films
KW  - development
KW  - design
KW  - paediatric
KW  - age-related
KW  - palatable
KW  - taste-masking
KW  - acceptable
N1  - Open Access
N2  - The development of paediatric medicines can be challenging since this is a different patient population with specific needs. A medicine designed for use in paediatric patients must consider the following aspects: patient population variability; the need for dose flexibility; route of administration; patient compliance; excipient tolerability. For example, the toxicity of excipients may differ in children compared to adults and children have different taste preferences. Globally, about 75% of drugs do not carry regulatory approval for use in children; worldwide, many medications prescribed for the treatment of paediatric diseases are used off-label, and less than 20% of package inserts have sufficient information for treating children. This book provides an update on both state-of-the-art methodology and operational challenges in paediatric formulation design and development. It aims at re-evaluating what is needed for more progress in the design and development of age-appropriate treatments for paediatric diseases, focusing on: formulation development; drug delivery design; efficacy, safety, and tolerability of drugs and excipients
UR  - https://mdpi.com/books/pdfview/book/3873
UR  - https://directory.doabooks.org/handle/20.500.12854/76438
ER  -